Manufacturer or GPO Program year 2025 Source: CMS Open Payments

GlaxoSmithKline, LLC.

PA, United States

CMS manufacturer 100000005449

Open in the dashboard

General payments

$171,319,977

2,231,988 payments

Research payments

$1,345,363,423

142,406 payments

Ownership & investment interest

$0

None reported

Through program year 2025, GlaxoSmithKline, LLC. reported paying $171,319,977 in general payments and $1,345,363,423 in research payments to U.S. physicians, teaching hospitals and other recipients.

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

14 rows
Year Kind Amount Payments
2025 General $22,993,880 346,594
2025 Research $282,572,048 18,172
2024 General $26,443,627 341,439
2024 Research $215,700,754 19,671
2023 General $35,405,444 439,057
2023 Research $207,613,061 20,661
2022 General $28,647,303 338,636
2022 Research $222,409,136 31,436
2021 General $24,003,944 307,839
2021 Research $182,982,345 21,269
2020 General $17,205,617 190,942
2020 Research $134,651,868 18,279
2019 General $16,620,162 267,481
2019 Research $99,434,211 12,918

Breakdown

Top recipients General payments · program year 2025
  1. Harry Dietz Clinical Genetics (M.D.) · Baltimore, MD $333,240 1 payment
  2. Cedric Franklin Rutland Critical Care Medicine · Riverside, CA $181,297 107 payments
  3. Michael Ott Pulmonary Disease · Eglin Afb, FL $146,966 200 payments
  4. John Chan Gynecologic Oncology · San Francisco, CA $137,769 78 payments
  5. Seth Oringher Chevy Chase, MD $134,951 118 payments
  6. Bob Geng Allergy & Immunology · San Diego, CA $134,049 95 payments
  7. Derrick Butler Family Medicine · Los Angeles, CA $132,342 115 payments
  8. Michael Mandel Pulmonary Disease · Larchmont, NY $130,129 128 payments
  9. Douglas Sborov Hematology & Oncology · Salt Lake City, UT $127,925 4 payments
  10. Joseph Han Otolaryngology · Norfolk, VA $126,653 66 payments
Top research recipients Research payments · program year 2025
  1. Barrow Neurological Institute At Saint Josephs Hospital And Medical Center $94,012,341 11 payments
  2. University Of Miami $16,237,446 114 payments
  3. Mayo Clinic $7,830,549 51 payments
  4. Quantum Leap Healthcare Collaborati $7,501,634 6 payments
  5. Ppd Development LP $7,014,521 57 payments
  6. Neurotrials LLC $6,604,170 6 payments
  7. Calcog Opco $5,789,469 6 payments
  8. University Of Texas MD Anderson Cancer Center $4,758,549 15 payments
  9. H Lee Moffitt Cancer Center And Research Institute Hospital INC $4,350,707 31 payments
  10. Translational Research In Oncology-US $4,186,830 15 payments
Products the payments named General payments · program year 2025
  1. Nucala Immunology $6,757,208 35% · 16,985 recipients
  2. Arexvy Respiratory $2,345,118 12% · 28,817 recipients
  3. Trelegy Ellipta Respiratory $2,335,978 12% · 37,193 recipients
  4. Benlysta Immunology $1,744,247 9% · 5,043 recipients
  5. Jemperli Oncology $1,573,808 8% · 4,871 recipients

The top 5 of 26 products; each share is of this company’s general payments naming a product in 2025. A payment can name up to five products, so these amounts overlap.

The top 25 products, free in the app

Specialties paid General payments · program year 2025
  1. Pulmonary Disease Internal Medicine $3,663,449 16% · 4,518 practitioners
  2. Gynecologic Oncology Obstetrics & Gynecology $1,663,422 7% · 486 practitioners
  3. Allergy & Immunology $1,561,590 7% · 1,682 practitioners
  4. Hematology & Oncology Internal Medicine $1,390,531 6% · 2,798 practitioners
  5. Family Medicine $1,232,691 6% · 14,732 practitioners

The top 5 of 232 specialties; each share is of this company’s general payments to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. California $3,323,770 14% · 9,095 recipients
  2. New York $2,046,985 9% · 6,064 recipients
  3. Florida $1,910,406 8% · 8,042 recipients
  4. Texas $1,886,163 8% · 8,206 recipients
  5. Pennsylvania $1,090,364 5% · 3,664 recipients

The top 5 of 54 states; each share is of this company’s general payments in 2025 where a state was reported.

The top 25 states, free in the app

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $84,392,856 30,601 payments
  2. Food and Beverage $42,855,647 2,164,905 payments
  3. Consulting Fee $32,716,875 11,280 payments
  4. Travel and Lodging $9,611,396 23,644 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $895,062 62 payments
  6. Grant $455,771 26 payments
  7. Space rental or facility fees (teaching hospital only) $335,823 119 payments
  8. Education $45,365 1,220 payments
  9. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $10,200 17 payments
  10. Gift $981 114 payments
2,231,988 general · 142,406 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers of drugs, devices and biologicals, and group purchasing organisations, are required to report the payments and transfers of value they make to physicians and teaching hospitals. This page shows what this company reported.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record